| 0.0973 -0 (-0.21%) | 03-04 09:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.08 |
1-year : | 0.12 |
| Resists | First : | 0.07 |
Second : | 0.1 |
| Pivot price | 0.06  |
|||
| Supports | First : | 0.01 | Second : | 0.01 |
| MAs | MA(5) : | 0.05 |
MA(20) : | 0.05 |
| MA(100) : | 0.1 |
MA(250) : | 0.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.4 |
D(3) : | 40.6 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 0.19 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ZOM ] has closed above bottom band by 14.2%. Bollinger Bands are 29.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.06 - 0.06 | 0.06 - 0.06 |
| Low: | 0.05 - 0.05 | 0.05 - 0.05 |
| Close: | 0.05 - 0.05 | 0.05 - 0.05 |
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Tue, 18 Mar 2025
Zomedica CEO Larry Heaton acquires $29,702 in common stock - Investing.com
Thu, 13 Mar 2025
Earnings call transcript: Zomedica Q4 2024 shows revenue growth - Investing.com
Wed, 05 Mar 2025
Zomedica Transitions to OTCQB Market Following NYSE Delisting - TipRanks
Tue, 04 Mar 2025
Press Release Distribution & PR Platform - ACCESS Newswire
Tue, 04 Mar 2025
Why Is Zomedica Moving to OTCQB? Company Explains NYSE Delisting Decision - Stock Titan
Wed, 12 Feb 2025
Press Release Distribution & PR Platform - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 998 (M) |
| Shares Float | 962 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 8.6 (%) |
| Shares Short | 49,230 (K) |
| Shares Short P.Month | 56,660 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | -214.7 % |
| Operating Margin | -147.5 % |
| Return on Assets (ttm) | -9.3 % |
| Return on Equity (ttm) | -24 % |
| Qtrly Rev. Growth | 1.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.89 |
| PEG Ratio | 0 |
| Price to Book value | 0.25 |
| Price to Sales | 2.02 |
| Price to Cash Flow | -2.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|